Annovis Bio (NYSE:ANVS – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Roth Capital in a research note issued on Monday, Benzinga reports. They currently have a $3.00 price target on the stock. Roth Capital‘s price target suggests a potential upside of 233.33% from the company’s previous close.
A number of other equities research analysts have also recently weighed in on the company. Wall Street Zen raised Annovis Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday. Weiss Ratings cut Annovis Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, November 10th. Finally, Canaccord Genuity Group reiterated a “buy” rating on shares of Annovis Bio in a research note on Tuesday, August 18th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $10.00.
Get Our Latest Analysis on Annovis Bio
Annovis Bio Stock Performance
Annovis Bio (NYSE:ANVS – Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. As a group, equities research analysts forecast that Annovis Bio will post -1.32 earnings per share for the current year.
Insider Buying and Selling
In other Annovis Bio news, Director Michael Hoffman acquired 5,000,000 shares of the stock in a transaction on Friday, November 6th. The shares were bought at an average price of $1.00 per share, with a total value of $5,000,000.00. Following the acquisition, the director owned 8,364,883 shares of the company’s stock, valued at $8,364,883. This trade represents a 148.59% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 15.92% of the stock is currently owned by insiders.
Institutional Trading of Annovis Bio
Several hedge funds have recently modified their holdings of the business. Nicholson Wealth Management Group LLC acquired a new position in Annovis Bio during the third quarter worth $25,000. Bank of New York Mellon Corp acquired a new stake in Annovis Bio in the second quarter valued at $29,000. StoneX Group Inc. lifted its holdings in Annovis Bio by 65.9% in the third quarter. StoneX Group Inc. now owns 23,996 shares of the company’s stock valued at $30,000 after acquiring an additional 9,531 shares during the period. Quadcap Wealth Management LLC purchased a new stake in shares of Annovis Bio during the 2nd quarter worth $30,000. Finally, Empowered Funds LLC acquired a new position in shares of Annovis Bio during the 3rd quarter worth $42,000. 15.83% of the stock is owned by institutional investors and hedge funds.
Annovis Bio Company Profile
Annovis Bio is a clinical-stage biotechnology company based in Malvern, Pennsylvania. Founded in 2008, the company researches and develops treatments for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease.
See Also
- Five stocks we like better than Annovis Bio
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.
